Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain

收购Mantle Therapeutics公司将增加多种旨在提高或替代大脑中frataxin的新疗法

Collaborations launched to evaluate gene therapy sequential dosing following treatment with LX2006 and explore cerebellar targeting to optimize outcomes in FA associated neurological disease

启动合作以评估LX2006治疗后基因疗法的序贯给药方案，并探索小脑靶向策略以优化弗里德赖希共济失调相关神经系统疾病的疗效

SUNRISE-FA 2 pivotal study continues enrollment and remains the company’s top priority development program; topline data on track for 2H 2027

SUNRISE-FA 2关键性研究正在持续入组，仍是公司最高优先级的开发项目；顶线数据预计将于2027年下半年如期公布

Disciplined capital allocation supports these strategic initiatives while maintaining cash runway into 2028

审慎的资本配置支持这些战略举措，同时确保现金跑道延续至2028年

Company to host webcast today at 8:00 AM ET

公司将于今日美东时间上午8点举行网络直播

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) --

纽约，2026年9月22日（环球电讯社）--

Lexeo Therapeutics, Inc

Lexeo Therapeutics, Inc.

. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including the signing of a definitive agreement to acquire Mantle Therapeutics Inc. and three new research collaborations supporting cerebellar-targeted development opportunities for frataxin gene therapy.

.（纳斯达克股票代码：LXEO）是一家专注于重塑高未满足需求遗传性疾病治疗路径的临床阶段公司，今日宣布了一系列战略交易，以扩大其在弗里德赖希共济失调（FA）领域的布局，包括签署收购Mantle Therapeutics Inc.的最终协议，以及达成三项新的研究合作，支持针对小脑的frataxin基因疗法开发机会。

Together, these transactions will simultaneously expand Lexeo's vision and capabilities beyond gene therapy, deepen the company’s focus on the multisystem burden of FA, and add multiple therapeutic approaches designed to increase or restore frataxin in the brain. These transactions are being pursued within Lexeo's existing balance sheet capacity, with cash runway guidance unchanged into 2028 and future investment decisions guided by predefined milestones to identify and prioritize the most compelling central nervous system (CNS) opportunities..

这些交易将同时拓展Lexeo在基因治疗之外的愿景和能力，加深公司对弗里德赖希共济失调（FA）多系统负担的关注，并增加多种旨在提高或恢复大脑中frataxin水平的治疗方法。这些交易是在Lexeo现有资产负债表能力范围内进行的，现金跑道指引维持至2028年不变，未来的投资决策将根据预设的里程碑来确定并优先处理最具潜力的中枢神经系统（CNS）机会。

“Our objective is to build the best-in-class therapeutic platform for the treatment of Friedreich ataxia,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “LX2006 remains our highest priority as the best-in-class treatment for FA cardiomyopathy, and the addition of Mantle’s pipeline, combined with new research collaborations will broaden our technology platform with multiple complementary CNS-targeted therapeutic strategies designed to restore frataxin in the brain and further improve outcomes for individuals living with FA.

“我们的目标是打造治疗弗里德赖希共济失调（Friedreich ataxia）的同类最佳治疗平台，”Lexeo Therapeutics 首席执行官 R. Nolan Townsend 表示。“LX2006 作为治疗 FA 心肌病的同类最佳疗法，仍然是我们的最高优先级；而 Mantle 产品管线的加入，结合新的研究合作，将通过多种互补的、针对中枢神经系统（CNS）的治疗策略来拓宽我们的技术平台，这些策略旨在恢复大脑中的 frataxin（弗拉塔辛）蛋白功能，并进一步改善 FA 患者的预后。”

Together, these initiatives will strengthen our leadership position in the disease category while supporting disciplined portfolio advancement and capital allocation.”.

这些举措将共同巩固我们在疾病治疗领域的领导地位，同时支持审慎的产品组合推进和资本配置。

Acquisition of Mantle Therapeutics Will Establish Lexeo's Multimodal Friedreich Ataxia Platform

收购Mantle Therapeutics将确立Lexeo的多模式弗里德赖希共济失调平台

On September 16

9月16日

th

泰国

, 2026, Lexeo entered into an agreement to acquire Mantle Therapeutics Inc. (“Mantle”), a private clinical stage company focused on developing multiple therapies for the treatment of FA. The acquisition will deepen Lexeo's focus on FA and strengthen its capabilities in addressing the neurologic aspects of disease..

2026年，Lexeo达成了一项收购Mantle Therapeutics Inc.（“Mantle”）的协议。Mantle是一家专注于开发多种治疗FA疗法的私人临床阶段公司。此次收购将加深Lexeo在FA领域的专注度，并增强其应对疾病神经学方面的能力。

The acquired portfolio will include:

收购的投资组合将包括：

LX3010 (MTL-104)

LX3010（MTL-104）

: a clinical stage, oral combination therapy designed to increase frataxin expression while addressing mitochondrial function and oxidative stress through complementary mechanisms (HDAC inhibition and NRf2). Early clinical data includes an approximately 6-point improvement in mFARS scores at 16 weeks and a mean nine-fold increase in frataxin protein levels from baseline in muscle biopsies across 11 FA patients..

：一种处于临床阶段的口服联合疗法，旨在通过互补机制（组蛋白去乙酰化酶[HDAC]抑制和Nrf2通路激活）提高frataxin表达，同时改善线粒体功能并缓解氧化应激。早期临床数据显示，在11名弗里德赖希共济失调（FA）患者中，治疗16周后mFARS评分平均提高约6分，肌肉活检显示frataxin蛋白水平较基线平均增加九倍。

LX3030 (MTL-707)

LX3030（MTL-707）

: a pre-clinical stage oral, tissue-penetrant true small molecule (sub-500Da) designed to increase production of endogenous frataxin in the central nervous system. LX3030 is a third-generation benzamide HDAC inhibitor that builds on published clinical work demonstrating oral benzamide HDACs increase frataxin in FA patients by epigenetic modulation and acetylation of chromatin.

：一种处于临床前阶段的口服、具有组织渗透性的真正小分子（分子量低于500道尔顿），旨在增加中枢神经系统中内源性frataxin的产生。LX3030是一种第三代苯甲酰胺类HDAC抑制剂，基于已发表的临床研究结果开发，这些研究证明口服苯甲酰胺类HDAC抑制剂可通过表观遗传调控和染色质乙酰化增加弗里德赖希共济失调（FA）患者体内的frataxin水平。

Preclinical studies of LX3030 have demonstrated robust increases in frataxin, supporting continued evaluation of LX3030 as a differentiated oral therapy..

LX3030的临床前研究已证实其能显著增加frataxin水平，支持继续将LX3030作为一种具有差异化的口服疗法进行评估。

LX3050 (MTL-501)

LX3050 (MTL-501)

: a pre-clinical stage recombinant human frataxin fused to a proprietary anti-TfR1 Fab, intended to directly replace the deficient frataxin protein and utilize a TfR1-targeting brain shuttle designed to cross the blood-brain barrier and increase delivery of frataxin to the brain. In vitro studies have demonstrated dose-responsive improvements in measures of mitochondrial function, providing early support for the program’s proposed mechanism..

：一种处于临床前阶段的重组人frataxin（FXN）蛋白，与专有的抗TfR1 Fab片段融合，旨在直接替代缺陷的frataxin蛋白，并利用靶向TfR1的脑穿梭系统穿越血脑屏障，提高frataxin向脑部的递送效率。体外研究已显示出线粒体功能指标的剂量依赖性改善，为该方案提出的作用机制提供了早期支持。

LX3070 (MTL-801)

LX3070 (MTL-801)

: a discovery stage ASO Fab conjugate program designed to stabilize

：一种旨在提高稳定性的发现阶段ASO-Fab偶联物项目

FXN

FXN

mRNA and thereby increase translation of endogenous frataxin protein. The program combines an RNA-targeted mechanism conjugated to a proprietary anti-TfR1 Fab. In vitro studies have demonstrated dose-responsive increases in frataxin.

mRNA，从而增加内源性frataxin蛋白的翻译。该方案结合了一种靶向RNA的作用机制，并与专有的抗TfR1 Fab片段偶联。体外研究已证实，frataxin水平呈现剂量依赖性的升高。

Under the terms of the agreement, Lexeo will pay Mantle shareholders $8.3 million in upfront consideration, consisting of a combination of cash and equity. The agreement also provides for up to $13.0 million in success-based milestone payments, payable in a combination of cash and equity upon the achievement of future clinical and regulatory milestones, bringing the total potential consideration to $21.3 million.

根据协议条款，Lexeo 将向 Mantle 股东支付 830 万美元的预付款对价，由现金和股权组合构成。协议还规定，在实现未来的临床和监管里程碑后，将以现金和股权组合形式支付最高达 1,300 万美元的基于成功条件的里程碑付款，使潜在对价总额达到 2,130 万美元。

Subject to customary closing conditions, the transaction is expected to close in the third quarter of 2026..

在满足惯例交割条件的前提下，预计该交易将于2026年第三季度完成。

Following closing, Lexeo will continue its evaluation of the acquired programs against predefined scientific, clinical, strategic and financial criteria and will prioritize investment in the opportunities demonstrating the strongest potential for clinical patient impact, regulatory success and shareholder value creation.

交易完成后，Lexeo将继续根据预先设定的科学、临床、战略和财务标准对收购的项目进行评估，并优先投资于那些在临床患者影响、监管成功以及股东价值创造方面展现出最强潜力的机会。

The Company's cash runway guidance into 2028 includes plans to advance one of the acquired programs into clinical development. The Company expects to provide a program prioritization update in early 2027 and submit an IND for its next FA development candidate in 2027..

公司的现金跑道指引涵盖至2028年，其中包括计划将其中一个收购项目推进至临床开发阶段。公司预计将在2027年初提供项目优先级更新，并于2027年提交其下一个纤维化（FA）开发候选药物的临床试验申请（IND）。

Together with LX2006, the expanded portfolio provides Lexeo with the technology to evaluate multiple biologic theses for the treatment of FA in the brain. These complementary therapies will be evaluated both as standalone treatments and in concert with LX2006, and all future clinical trials are expected to include a treatment arm for patients previously treated with LX2006.

与LX2006一起，扩展的产品组合为Lexeo提供了评估多种生物制剂治疗脑内FA（弗里德赖希共济失调）的技术。这些互补疗法将作为独立治疗方案以及与LX2006联合使用进行评估，并且所有未来的临床试验预计都将包括一个针对先前接受过LX2006治疗患者的治疗组。

.

。

Strategic Collaborations Supporting Sequential Dosing of CNS Targeted Frataxin Gene Therapy

支持中枢神经系统靶向弗里达辛基因疗法序贯给药的战略合作

Lexeo has established three collaborations to evaluate cerebellar-targeted sequential dosing of frataxin gene therapy, all designed to be complementary to systemically administered LX2006.

Lexeo已建立三项合作，以评估靶向小脑的弗里达辛基因疗法序贯给药方案，这些方案均旨在与全身给药的LX2006形成互补。

Weill Cornell Medicine Cerebellar-Targeted Sequential Dosing Research

威尔康奈尔医学院小脑靶向序贯给药研究

: Lexeo entered into a Sponsored Research Agreement with Weill Cornell Medicine to evaluate intra-cisternal administration of LX2006 following systemic dosing in large animal models. The collaboration is intended to further the understanding and translation of cerebellar-targeted sequential dosing, and to evaluate dosing parameters and immune-suppression strategies that may support repeat administration..

Lexeo 与威尔康奈尔医学院签订了一项赞助研究协议，以评估在大型动物模型中全身给药后脑池内给予 LX2006 的情况。此次合作旨在进一步理解和转化针对小脑的序贯给药方案，并评估可能支持重复给药的剂量参数和免疫抑制策略。

Vivet Therapeutics IgG-Degrading VTX-PID Enzyme Option Agreement

Vivet Therapeutics IgG降解酶VTX-PID选择权协议

: Lexeo entered into an option agreement with Vivet Therapeutics providing the opportunity to secure an exclusive license to VTX-PID, an IgG-degrading enzyme intended to support immune-suppression strategies that may expand treatable population with immunization against AAV and facilitate repeat administration of LX2006..

Lexeo 与 Vivet Therapeutics 达成了一项期权协议，从而获得确保 VTX-PID 独家许可权的机会。VTX-PID 是一种 IgG 降解酶，旨在支持免疫抑制策略，这些策略可能扩大针对 AAV 的免疫治疗人群范围，并促进 LX2006 的重复给药。

Apertura Gene Therapy Novel CNS Capsid (CapX) Option Agreement

Apertura 基因疗法新型中枢神经系统衣壳（CapX）期权协议

: Lexeo entered into an option agreement with Apertura Gene Therapy providing the opportunity to secure a license to a novel, intravenously administered, blood-brain barrier-crossing capsid that is expected to enable a less invasive route of administration to the CNS following initial systemic administration of LX2006..

Lexeo 与 Apertura Gene Therapy 签订了一项期权协议，从而获得获取一种新型静脉注射、可穿越血脑屏障的衣壳的许可权的机会；该衣壳有望在首次全身给予 LX2006 后，实现侵入性更低的中枢神经系统给药途径。

Similarly, Lexeo intends to evaluate the outcomes of these research collaborations against predefined scientific, clinical and financial criteria and prioritize investment in opportunities with the greatest potential to advance into clinical development and provide FA patients with a sequential CNS-dosing option to complement prior systemic administration of LX2006..

同样，Lexeo 计划根据预先设定的科学、临床和财务标准评估这些研发合作的成果，并优先投资于最具潜力推进至临床开发阶段的项目，为范可尼贫血（FA）患者提供一种序贯中枢神经系统给药方案，以补充此前 LX2006 的全身给药。

Expanded Vision to Reflect Strategic Focus

拓展视野以体现战略重点

Lexeo is introducing an expanded vision reflecting the company’s focus on the treatment of genetic diseases with high unmet need in both the cardiovascular and neurological space. The refreshed positioning aligns with Lexeo's growing Friedreich ataxia platform and expanded portfolio across multiple modalities outside of gene therapy..

Lexeo 正在推出一个扩展后的愿景，反映出公司专注于治疗心血管和神经领域中存在高度未满足需求的遗传性疾病。这一焕然一新的定位与 Lexeo 不断发展的弗里德赖希共济失调平台以及其在基因疗法之外多种技术途径上扩展的产品组合相契合。

Continued Advancement of LX2006

LX2006 的持续进展

LX2006 continues to advance enrollment in the SUNRISE-FA 2 pivotal study, which remains Lexeo's highest operational and capital-allocation priority. The program remains on track to provide a topline data readout in the second half of 2027. The Company believes LX2006 has the potential to become the first disease-modifying therapy specifically targeting Friedreich ataxia cardiomyopathy..

LX2006 继续推进 SUNRISE-FA 2 关键性研究的入组工作，该研究仍是 Lexeo 公司在运营和资本配置方面的最高优先级项目。该项目按计划推进，预计将于 2027 年下半年公布顶层数据结果。公司认为，LX2006 有潜力成为首款专门针对弗里德赖希共济失调心肌病的疾病修饰疗法。

Corporate Webcast Details

企业网络研讨会详情

Lexeo Therapeutics will host a webcast at 8:00 AM ET today, September 22, 2026. Analysts and investors can participate by accessing the webcast live on the

Lexeo Therapeutics 将于美国东部时间今天上午 8:00（2026 年 9 月 22 日）举行网络直播。分析师和投资者可通过以下方式实时接入网络直播参与：

Events & Presentations

活动与演讲

page in the Investors section of Lexeo’s website,

Lexeo 网站投资者关系板块中的页面，

www.lexeotx.com

www.lexeotx.com

. The webcast will be archived on the company’s website following the call.

网络直播将在电话会议结束后存档于公司网站。

About Lexeo Therapeutics

关于 Lexeo Therapeutics

Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach.

Lexeo Therapeutics 是一家总部位于纽约市的临床阶段公司，致力于改变遗传性疾病的发展轨迹。通过推进开创性科学，Lexeo 力求在心血管和神经系统遗传性疾病的治疗领域树立新标准，为实现曾经被认为遥不可及的患者预后绘制路径。

The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need..

该公司正在推进一系列治疗候选药物，旨在解决疾病的潜在遗传病因，包括用于弗里德赖希共济失调（FA）的LX2006、用于桥粒斑蛋白-2（PKP2）致心律失常性心肌病的LX2020，以及其他针对具有高未满足需求的毁灭性疾病的候选药物。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警示性说明

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, the anticipated benefits of its current product candidates, the timing for receipt and announcement of data from its clinical trials, the timing and likelihood of potential regulatory developments, trial design changes and approval, expectations regarding the time period over which Lexeo’s capital resources will be sufficient to fund its anticipated operations and estimates regarding Lexeo’s financial condition, the expected closing of the proposed acquisition of Mantle Therapeutics Inc.

本新闻稿中的某些陈述可能构成联邦证券法意义上的“前瞻性陈述”，包括但不限于：Lexeo 对其当前候选产品和研发计划的预期与规划；其当前候选产品的预期获益；临床试验数据的接收和公布时间；潜在监管进展、试验设计变更及获批的时间和可能性；关于 Lexeo 的资本资源足以支持其预期运营的时间段的预期；以及对 Lexeo 财务状况的估计；拟议收购 Mantle Therapeutics Inc. 交易的预期交割。

and the satisfaction of the conditions thereto, the anticipated benefits of the proposed acquisition and the acquired programs, the timing and outcome of Lexeo’s evaluation of the acquired programs and research collaborations against predefined criteria, the expected timing of a program prioritization update, the expected submission of an IND for Lexeo’s next Friedreich ataxia development candidate, and the potential achievement of future clinical and regulatory milestones.

以及满足相关条件、拟议收购及被收购项目的预期收益、Lexeo根据预定义标准对被收购项目及研发合作进行评估的时间和结果、项目优先级更新的预计时间、Lexeo下一个弗里德赖希共济失调开发候选药物的临床试验申请（IND）的预期提交时间，以及未来临床和监管里程碑的潜在达成情况。

Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements.

“可能”、“或许”、“将”、“目标”、“打算”、“应当”、“可以”、“能够”、“会”、“预期”、“相信”、“设计”、“估计”、“预测”、“潜在”、“开发”、“计划”等词语，或其否定形式，以及类似表述，或关于意图、信念或当前预期的陈述，均属于前瞻性陈述。

While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company a.

尽管 Lexeo 认为这些前瞻性陈述是合理的，但不应过度依赖任何此类前瞻性陈述。这些前瞻性陈述基于公司当前可获得的信息。

Media Response:

媒体回应：

Media@lexeotx.com

Media@lexeotx.com

Investor Response:

投资者回应：

Ashley Kaplowitz

阿什利·卡普洛维茨

akaplowitz@lexeotx.com

akaplowitz@lexeotx.com